Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.80 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667587 | 0.89 | MAPK13 (1.00) | RAF1MAPK13MAPK14ERBB2MAPK11 | |
| SCHEMBL5575739 | 0.83 | MAPK14 (1.00) | RAF1MAPK13MAPK14MAPK11BRAF | |
| SCHEMBL16870246 | 0.81 | MAPK14 (0.78) | RAF1MAPK13MAPK14BRAF | |
| SCHEMBL667132 | 0.81 | MAPK14 (0.80) | RAF1MAPK13MAPK14ERBB2MAPK11 | |
| SCHEMBL9923556 | 0.80 | MAPK14 (1.00) | RAF1MAPK13MAPK14MAPK11BRAF | |
| SCHEMBL18407354 | 0.79 | MAPK14 (0.81) | RAF1MAPK13MAPK14ERBB2MAPK11 | |
| SCHEMBL667815 | 0.79 | RAF1 (0.60) | RAF1MAPK13MAPK14BRAF | |
| SCHEMBL5575743 | 0.79 | MAPK14 (0.59) | RAF1MAPK13MAPK14MAPK11BRAF | |
| SCHEMBL3300214 | 0.77 | MAPK14 (0.84) | RAF1MAPK13MAPK14MAPK11BRAF | |
| SCHEMBL1410387 | 0.77 | MAPK13 (0.68) | RAF1MAPK13MAPK14MAPK11BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | claimed |
| EP-1047418-B1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-07-27 | — | — | EP | claimed |
| CN-1544420-A | Inhibition of raf kinase using substituted heterocyclic ureas | — | 2004-11-10 | — | — | CN | claimed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| EP-1047418-B1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| CN-1544420-A | Inhibition of raf kinase using substituted heterocyclic ureas | — | 2004-11-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | RAF1 2/4885MAPK13 90/4885MAPK14 127/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | RAF1 2/4885MAPK13 90/4885MAPK14 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.